Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Cardiac transplantation with cyclosporin A and prednisone

Griffith, BP and Hardesty, RL and Deeb, GM and Starzl, TE and Bahnson, HT (1982) Cardiac transplantation with cyclosporin A and prednisone. Annals of Surgery, 196 (3). 324 - 329. ISSN 0003-4932

Accepted Version
Available under License : See the attached license file.

Download (1MB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


Influenced by continuing improvement in results from Stanford, cardiac transplantation was resumed at the University Health Center of Pittsburgh in June 1980. Cyclosporin A (CyA) became available to the authors early in 1981. This report describes the preliminary experience with 21 patients who were treated between March 1981 and April 10, 1982 with cyclosporin A and low-dose steroids. Ages ranged from eight to 53 years, median 46 years. Median age of ten patients disabled because of idiopathic myocardiopathy was 33 years; it was 45 years in the 11 suffering from ischemic heart disease. Sixteen of the 21 patients survived. Eleven have survived for three months, of which six have survived for six months, giving a cumulative survival of 74 and 66%, respectively. Four died perioperatively; one died at six weeks and one at four months. Hyperacute rejection resulted in one death at 12 hours even though the warm and cold lymphocytotoxic crossmatch for T and B cells was negative as evaluated by trypan blue. The two late deaths were related to infection. No late death has occurred because of rejection, and a unique feature is that three recipients with a lymphocytotoxic mismatch did not develop hyperacute rejection. The number of infectious episodes and nonviral infections appears to be less than that associated with the use of azathiaprine and larger doses of steroids. Cyclosporin A (5-10 mg/kg/d) and low-dose prednisone (rapidly tapered in seven days from 200 mg to 15-20 mg/d) is effective in preventing early morbid rejection of the transplanted heart.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Griffith, BP
Hardesty, RL
Deeb, GM
Starzl, TEtes11@pitt.eduTES11
Bahnson, HT
Centers: Other Centers, Institutes, Offices, or Units > Thomas E. Starzl Transplantation Institute
Date: 1 January 1982
Date Type: Publication
Journal or Publication Title: Annals of Surgery
Volume: 196
Number: 3
Page Range: 324 - 329
DOI or Unique Handle: 10.1097/00000658-198209000-00011
Institution: University of Pittsburgh
Refereed: Yes
ISSN: 0003-4932
Other ID: uls-drl:31735062114602, Starzl CV No. 492
Date Deposited: 08 Apr 2010 17:08
Last Modified: 02 Feb 2019 13:57


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item